文献速递消化系统肿瘤

胰腺导管腺癌的免疫治疗:新兴领域?

Immunotherapy in pancreatic ductal adenocarcinoma: an emerging entity?
PubMed 文献 · Ann Oncol · 2017-01-01

本文综述了免疫治疗在胰腺导管腺癌(PDAC)中的研究现状。尽管在黑色素瘤、肺癌、肾癌和膀胱癌等实体瘤中观察到免疫治疗策略有前景的临床活性,但PDAC中免疫治疗的价值尚未证实。转化和早期临床研究显示抗肿瘤免疫激活,但近期晚期临床试验未证实早期希望,MSI-High PDAC患者除外。

要点

  • PDAC中免疫治疗尚未证实价值,MSI-High PDAC患者例外。
  • PDAC低免疫原性、免疫豁免、复杂微环境和遗传可塑性可部分解释试验失败。
  • 这些挑战加深了对PDAC免疫治疗的理解,有望指导未来方向。

核心结论

  • 免疫治疗在PDAC中除MSI-High患者外尚未证实价值,但进展有望。

研究设计与样本

  • 综述,未报告检索范围与样本量。

主要发现

  • 多种免疫治疗策略在黑色素瘤、肺癌、肾癌和膀胱癌等实体瘤中观察到有前景的临床活性。
  • 转化和早期临床研究显示PDAC中抗肿瘤免疫激活。
  • 近期晚期临床试验未证实PDAC中免疫治疗的早期希望,MSI-High PDAC患者除外。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The genomic-plasticity of the immune system creates a broad immune repertoire engaged to tackle cancer cells. Promising clinical activity has been observed with several immune therapy strategies in solid tumors including melanoma, lung, kidney, and bladder cancers, albeit as yet immunotherapy-based treatment approaches in pancreatic ductal adenocarcinoma (PDAC) remain to have proven value. While translational and early clinical studies have demonstrated activation of antitumor immunity, most recent late-phase clinical trials have not confirmed the early promise in PDAC except in MSI-High PDAC patients. These results may in part be explained by multiple factors, including the poorly immunogenic nature of PDAC along with immune privilege, the complex tumor microenvironment, and the genetic plasticity of PDAC cells. These challenges have led to disappointments in the field, nonetheless they have also advanced our understanding that may tailor the future steps for immunotherapy for PDAC. Therefore, there is significant hope that progress is on the horizon.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Sahin IH, Askan G, Hu ZI, et al. Immunotherapy in pancreatic ductal adenocarcinoma: an emerging entity? Ann Oncol. 2017. PMID: 28945842. doi:10.1093/annonc/mdx503

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。